安罗替尼联合多西他赛三线治疗晚期肺鳞癌的临床研究

    Clinical study on anlotinib combined with docetaxel in the third-line treatment of advanced squamous cell lung carcinoma

    • 摘要:
      目的观察安罗替尼联合多西他赛三线治疗晚期肺鳞癌病人的有效性和安全性。
      方法选取100例晚期肺鳞癌病人,根据随机数表法分为对照组(n=44)与观察组(n=56),对照组给予地塞米松联合多西他赛,观察组在对照组基础上联合安罗替尼。比较2组临床疗效、用药不良反应、生存情况及生存质量。
      结果治疗后,2组客观缓解率、疾病控制率、不良反应发生率、死亡率差异均无统计学意义(P>0.05)。对照组总生存时间为10.21个月(95%CI:7.290~13.139),观察组病人总生存时间为12.65个月(95%CI:10.588~14.712)。治疗后,2组功能领域与总体健康状况评分高于治疗前(P < 0.05),症状领域与癌症症状评分低于治疗前(P < 0.05);且观察组功能领域与总体健康状况评分明显高于对照组(P < 0.01),症状领域与癌症症状评分明显低于对照组(P < 0.01)。
      结论盐酸安罗替尼与多西他赛联合用于晚期肺鳞癌的三线治疗中可延长病人的生存时间、改善生活质量,且未明显增加不良反应。

       

      Abstract:
      ObjectiveTo observe the effectiveness and safety of anlotinib combined with docetaxel in the third-line treatment of advanced squamous cell lung carcinoma.
      MethodsOne hundred patients with advanced squamous cell lung carcinoma were selected and divided into control group (n=44) and observation group (n=56) according to the random number table method.The control group was treated with dexamethasone and docetaxel, and the observation group was treated with anlotinib additionally on the basis of control group.The clinical efficacy, adverse reactions, survival and quality of life were compared between the two groups.
      ResultsAfter treatment, there was no statistical difference in the objective remission rate, disease control rate, incidence of adverse reactions and mortality between the two groups (P>0.05).The overall survival time of control group and observation group was 10.21 months (95%CI:7.290-13.139) and 12.65 months (95%CI:10.588-14.712), respectively.After treatment, the scores of functional area and general health status of the two groups were higher than those before treatment (P < 0.05), and the scores of symptom area and cancer symptom were lower than those before treatment (P < 0.05);the scores of functional area and general health status in the observation group were significantly higher than those in control group (P < 0.01), and the scores of symptom area and cancer symptom in observation group were significantly lower than those in control group (P < 0.01).
      ConclusionsThe combination of amlotinib hydrochloride and docetaxel in the third-line treatment of advanced squamous cell lung carcinoma can prolong survival time, improve quality of life, and not significantly increase adverse reactions of patients.

       

    /

    返回文章
    返回